CD16抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Ramos cells using CD16 mouse mAb (green) and negative control (red).    

  
  

CD16 antibodies target the CD16 antigen, a low-affinity Fc gamma receptor III (FcγRIII) expressed primarily on natural killer (NK) cells, macrophages, neutrophils, and a subset of T cells. CD16 exists as two isoforms: CD16a (FcγRIIIA), a transmembrane protein on NK cells and macrophages, and CD16b (FcγRIIIB), a glycosylphosphatidylinositol (GPI)-anchored form on neutrophils. These receptors bind the Fc region of IgG antibodies, facilitating antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, and cytokine release, thereby bridging innate and adaptive immunity.

CD16 antibodies are pivotal in research and therapeutics. In immunotherapy, they enhance NK cell-mediated tumor targeting by engaging CD16a to amplify ADCC, a mechanism exploited by monoclonal antibodies like rituximab and trastuzumab. Conversely, CD16-blocking antibodies may mitigate inflammatory diseases by dampening immune activation. Diagnostic applications include flow cytometry to identify NK cells or monitor receptor density in immune disorders. Recent advances include bispecific antibodies that co-engage CD16 and tumor antigens, redirecting NK cytotoxicity. Challenges include CD16 polymorphism-related variability in antibody binding and effector functions. Overall, CD16 antibodies remain critical tools for modulating immune responses and advancing cancer and autoimmune disease therapies.